Abstract | OBJECTIVE: METHODS: RESULTS: Massive hepatocyte apoptosis were detected in the model group. The apoptotic index was clearly reduced in the pre-treatment model group [(26 ± 11)% vs (77 ± 20)%, P < 0.01]. And the activity of caspase-3 was also lower in the pre-treatment model group than that in the model group [(2.50 ± 0.83) pmol · min(-1) · mg(-1) vs (3.76 ± 0.42) pmol · min(-1) · mg(-1), P < 0.01]. In addition, the serum and liver tissue levels of TNF-α, IL-1β and IFN-γ in the pre-treatment model group were significantly lower than those in the model group[1.69 ± 0.47 vs 3.57 ± 0.79, 0.31 ± 0.02 vs 0.46 ± 0.06, 2.81 ± 0.72 vs 3.35 ± 0.84, (233 ± 36) pg/ml vs (441 ± 157) pg/ml, (228 ± 21) pg/ml vs (364 ± 20) pg/ml, (93.8 ± 5.2) pg/ml vs (180.3 ± 4.3) pg/ml, all P < 0.01]. CONCLUSION: LPS/D-GalN-induced acute hepatocyte apoptosis can be inhibited by a pretreatment of urantide through an inhibition of expression and secretion of proinflammatory cytokines. The UII/UT receptor system plays a pivotal role in the liver immuno-inflammatory injury of acute liver failure (ALF). And it may become a new drug target of ALF therapy.
|
Authors | Fang-ping Yu, Liang Zhao, Liang-ming Liu, Dong-yu Liang, Dao-hua Yang, Fang-fang Zhang, Chang-gen Ye |
Journal | Zhonghua yi xue za zhi
(Zhonghua Yi Xue Za Zhi)
Vol. 91
Issue 47
Pg. 3358-62
(Dec 20 2011)
ISSN: 0376-2491 [Print] China |
PMID | 22333205
(Publication Type: English Abstract, Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Interleukin-1beta
- Peptide Fragments
- Receptors, G-Protein-Coupled
- Tumor Necrosis Factor-alpha
- Urotensins
- urotensin II (4-11), Pen(5)-Trp(7)-Orn(8)-
- urotensin II receptor, mouse
- Interferon-gamma
- Casp3 protein, mouse
- Caspase 3
|
Topics |
- Animals
- Apoptosis
(drug effects)
- Caspase 3
(metabolism)
- Hepatocytes
(drug effects, metabolism, pathology)
- Interferon-gamma
(metabolism)
- Interleukin-1beta
(metabolism)
- Liver Failure, Acute
(chemically induced, pathology)
- Male
- Mice
- Mice, Inbred BALB C
- Peptide Fragments
(pharmacology)
- Receptors, G-Protein-Coupled
(antagonists & inhibitors)
- Tumor Necrosis Factor-alpha
(metabolism)
- Urotensins
(pharmacology)
|